Click HERE for Coronavirus COVID-19 Links for the UCSF Cancer Community

Science and medicine have embraced Twitter. Should you?

Twitter’s reach and ability to influence have made it a critical communication tool in all areas of life and work. Learn how UCSF cancer experts are harnessing the value of Twitter's bite-sized benefits.

UCSF Medical Center Ranks 1st Nationwide in Neuro, Among Top 10 Hospitals for 2021-22

UCSF Medical Center has been recognized as the nation’s best hospital for neurology and neurosurgery, and among the country’s premier medical centers overall, in the 2021-22 Best Hospitals survey by U.S. News & World Report.

Thirteen Cancer Research Projects Funded in Spring 2021 RAP Cycle

Thirteen investigators were awarded grants in support of cancer research projects in the Spring 2021 cycle of the UCSF Resource Allocation Program (RAP), spanning a range of topics from health equity to therapy resistance to developing new screening methods.

HDFCCC Pledges Funds for Bold, Provocative Ideas

Cancer Center leadership is calling on members to submit their boldest ideas for future research projects and collaborations that will drive funding priorities and scientific emphasis over the coming decade.

Cell Bots courtesy Wendell Lim Lab, UCSF

Beyond CAR-T: New Frontiers in Living Cell Therapies

The idea of using cells as medicine emerged with bone marrow transplants, and then CAR-T therapy for blood cancers. Now, scientists are beginning to engineer much more complex living therapeutics by tapping into the innate capabilities of living cells to treat a growing list of diseases.

Targeted Therapy for ‘Undruggable’ Lung Cancer Stems from Decades of UCSF Research

A recent FDA-approved treatment for non-small cell lung cancer rests on a foundation of work by UCSF scientists. As a result, drugging other KRAS-driven cancers is no longer unthinkable.

Examining Leukemia Risks Among Children with Down Syndrome

A recent collaborative retrospective cohort study from UC San Francisco, UC Davis and others confirmed that Down syndrome remains a strong risk factor for childhood leukemia, and associations with AML are stronger than previously reported.

Living Therapeutics Initiative Will Accelerate Development and Delivery of Revolutionary Treatments

UC San Francisco is launching a new initiative to propel the development of living therapeutics – a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease – and bring them quickly to patients.

Uniting the Black Community to Defeat COVID

Q&A with Kim Rhoads, founder of Umoja Health Partners and director of the Office of Community Engagement at the UCSF Helen Diller Family Comprehensive Cancer Center.